Journal of Global Infectious DiseasesOfficial Publishing of INDUSEM and OPUS 12 Foundation, Inc. Users online:986  
Print this pageEmail this pageSmall font sizeDefault font sizeIncrease font size     
Home About us Editors Ahead of Print Current Issue Archives Search Instructions Subscribe Advertise Login 
 
This article has been cited by
1DTaP-IPV-Hep B-Hib Vaccine (Hexaxim®)
Paul L. McCormack
Pediatric Drugs.2013;15(1)59
[DOI]
2Multiplex immunoassay for in vitro characterization of acellular pertussis antigens in combination vaccines
Valentina Agnolon,Cristina Bruno,Bruno Galletti,Elena Mori,Mildred Ugozzoli,Carlo Pergola,Derek T. O’Hagan,Barbara C. Baudner
Vaccine.2016;34(8)1040
[DOI]
3Evaluation of intranasal and subcutaneous route of immunization in neonatal mice using DODAB-BF as adjuvant with outer membrane vesicles of Neisseria meningitis B
Fernanda Ayane de Oliveira Santos,Nilton Lincopan,Elizabeth De Gaspari
Immunobiology.2018;223(12)750
[DOI]
4Hexavalent vaccines in preterm infants: an update by Italian Society of Pediatric Allergy and Immunology jointly with the Italian Society of Neonatology
E. Chiappini,C. Petrolini,C. Caffarelli,M. Calvani,F. Cardinale,M. Duse,A. Licari,S. Manti,A. Martelli,D. Minasi,M. Miraglia Del Giudice,GB. Pajno,C. Pietrasanta,L. Pugni,MA. Tosca,F. Mosca,GL. Marseglia
Italian Journal of Pediatrics.2019;45(1)750
[DOI]
5Hexavalent vaccines in preterm infants: an update by Italian Society of Pediatric Allergy and Immunology jointly with the Italian Society of Neonatology
Shwu-Maan Lee,Vincent Turula,Bradford Powell,Mikkel Nissum,Mariagrazia Pizza,Claudia Magagnoli,Niranjan M. Kumar
Italian Journal of Pediatrics.2015;45(1)187
[DOI]
6Recommendation for use of diphtheria and tetanus toxoids and acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b conjugate, and hepatitis B vaccine in infants
Hye-Kyung Cho,Su Eun Park,Yae-Jean Kim,Dae Sun Jo,Yun-Kyung Kim,Byung-Wook Eun,Taek-Jin Lee,Jina Lee,Hyunju Lee,Ki Hwan Kim,Eun Young Cho,Jong Gyun Ahn,Eun Hwa Choi
Clinical and Experimental Pediatrics.2021;64(12)602
[DOI]
7What can we learn from the microbial ecological interactions associated with polymicrobial diseases?
J.F. Antiabong,W. Boardman,A.S. Ball
Veterinary Immunology and Immunopathology.2014;158(1-2)30
[DOI]
8Booster Vaccination: The Role of Reduced Antigen Content Vaccines as a Preschool Booster
Giovanni Gabutti,Cecilia Trucchi,Michele Conversano,Giambattista Zivelonghi,Giorgio Zoppi
BioMed Research International.2014;2014(1-2)1
[DOI]
9HBV seroprevalence after 25 years of universal mass vaccination and management of non-responders to the anti-Hepatitis B vaccine: An Italian study among medical students
Francesco P. Bianchi,Maria S. Gallone,Maria F. Gallone,Angela M. V. Larocca,Luigi Vimercati,Michele Quarto,Silvio Tafuri
Journal of Viral Hepatitis.2019;26(1)136
[DOI]
10Safety, immunogenicity and persistence of immune response to the combined diphtheria, tetanus, acellular pertussis, poliovirus and Haemophilus influenzae type b conjugate vaccine (DTPa-IPV/Hib) administered in Chinese infants
Yanping Li,Rong Cheng Li,Qiang Ye,Changgui Li,You Ping Liu,Xiao Ma,Yanan Li,Hong Zhao,Xiaoling Chen,Deepak Assudani,Naveen Karkada,Htay Htay Han,Olivier Van Der Meeren,Narcisa Mesaros
Human Vaccines & Immunotherapeutics.2017;13(3)588
[DOI]
11Landscape of vaccine access and health technology assessment role in decision-making process in ASEAN countries
Suthira Taychakhoonavudh,Woralak Chumchujan,Raymond Hutubessy,Nathorn Chaiyakunapruk
Human Vaccines & Immunotherapeutics.2020;16(7)1728
[DOI]
12Co-administration of vaccines: a focus on tetravalent Measles-Mumps-Rubella-Varicella (MMRV) and meningococcal C conjugate vaccines
Paolo Bonanni,Sara Boccalini,Angela Bechini,Ornella Varone,Giulio Matteo,Federica Sandri,Giovanni Gabutti
Human Vaccines & Immunotherapeutics.2020;16(6)1313
[DOI]
13Nanotechnology for making a paradigm shift in COVID-19 vaccine
Paolo Bonanni,Sara Boccalini,Angela Bechini,Ornella Varone,Giulio Matteo,Federica Sandri,Giovanni Gabutti
Clinical Complementary Medicine and Pharmacology.2022;2(1)100017
[DOI]
14Versatile and on-demand biologics co-production in yeast
Jicong Cao,Pablo Perez-Pinera,Ky Lowenhaupt,Ming-Ru Wu,Oliver Purcell,Cesar de la Fuente-Nunez,Timothy K. Lu
Nature Communications.2018;9(1)100017
[DOI]
15DTaP-IPV-Hep B-Hib vaccine (Hexyon®/Hexacima®): a guide to its use in the primary and booster vaccination of infants and toddlers in Europe
Katherine A. Lyseng-Williamson,Paul L. McCormack
Drugs & Therapy Perspectives.2013;29(11)329
[DOI]
16Studies on formulation of a combination heat killed immunogen from diarrheagenic Escherichia coli and Vibrio cholerae in RITARD model
Priyadarshini Mukherjee,Vivek Mondal,Ushasi Bhaumik,Ritam Sinha,Sounak Sarkar,Soma Mitra,Debaki Ranjan Howlader,Suhrid Maiti,Asish Kumar Mukhopadhyay,Shanta Dutta,Hemanta Koley
Microbes and Infection.2019;21(8-9)368
[DOI]
17Separation of three strains of polio virus by capillary zone electrophoresis and study of their interaction with aluminum oxyhydroxide
Camille Malburet,Laurent Leclercq,Jean-François Cotte,Jérôme Thiebaud,Hervé Cottet
Journal of Chromatography A.2022;1667(8-9)462838
[DOI]
18DTaP5-HB-IPV-Hib Vaccine (Vaxelis®): A Review of its Use in Primary and Booster Vaccination
Yahiya Y. Syed
Pediatric Drugs.2017;19(1)69
[DOI]
19Peptides, Antibodies, Peptide Antibodies and More
Nicole Trier,Paul Hansen,Gunnar Houen
International Journal of Molecular Sciences.2019;20(24)6289
[DOI]
20Immunogenicity and safety of a liquid Pentavalent (DTwP-Hb-Hib) combination vaccine manufactured by Human Biologicals Institute in 6–8?weeks old healthy infants: A phase III, randomized, single blind, non-inferiority study
Sai Krishna Susarla,Madhu Gupta,Mukta Mantan,Ramchandra Dhongade,Sheila Bhave,Rajat Kumar Das,Rajib Kumar Ray,T. Ramesh Babu,M.D. Ravi,B. Krishnamurthy,Saji James,G. Sandhya,M. Satish,Devi Prasad Sahoo
Vaccine.2019;37(36)5452
[DOI]
21Protection against Staphylococcus aureus and tetanus infections by a combined vaccine containing SasA and TeNT-Hc in mice
Yilong Yang,Rui Yu,Xiuxu Yang,Shuling Liu,Ting Fang,Xiaohong Song,Lihua Hou,Changming Yu,Junjie Xu,Ling Fu,Shaoqiong Yi,Wei Chen
Molecular Medicine Reports.2017;15(4)2369
[DOI]
22Challenges for the pharmaceutical technical development of protein coformulations
Claudia Mueller,Ulrike Altenburger,Silke Mohl
Journal of Pharmacy and Pharmacology.2018;70(5)666
[DOI]
23Bivalent mucosal peptide vaccines administered using the LCP carrier system stimulate protective immune responses against Streptococcus pyogenes infection
Kai Schulze,Thomas Ebensen,Saranya Chandrudu,Mariusz Skwarczynski,Istvan Toth,Colleen Olive,Carlos A. Guzman
Nanomedicine: Nanotechnology, Biology and Medicine.2017;13(8)2463
[DOI]
24An Overview of Structural Features of Antibacterial Glycoconjugate Vaccines That Influence Their Immunogenicity
Farjana Khatun,Rachel J. Stephenson,Istvan Toth
Chemistry - A European Journal.2017;23(18)4233
[DOI]
25Hib antibody responses in infants following diphtheria, tetanus, acellular pertussis, and conjugated Haemophilus influenzae type b (Hib) combination vaccines with decreasing amounts of tetanus toxoid
Henry H. Bernstein,Elisabeth R. Seyferth
Vaccine.2017;35(48)6707
[DOI]
26Preparation and testing of a Haemophilus influenzae Type b/Hepatitis B surface antigen conjugate vaccine
So Jung An,Joo Sung Woo,Myung Hwa Chae,Sudeep Kothari,Rodney Carbis
Vaccine.2015;33(13)1614
[DOI]
27Combined vaccines for prophylaxis of infectious conditions
Pravin Shende,Mansi Waghchaure
Artificial Cells, Nanomedicine, and Biotechnology.2019;47(1)695
[DOI]
28Combined vaccines for prophylaxis of infectious conditions
Federico Martinón-Torres
Artificial Cells, Nanomedicine, and Biotechnology.2021;47(1)207
[DOI]
29Immunogenicity and safety of primary and booster vaccination with 2 investigational formulations of diphtheria, tetanus andHaemophilus influenzaetype b antigens in a hexavalent DTPa-HBV-IPV/Hib combination vaccine in comparison with the licensedInfanrix hexa
Timo Vesikari,Luis Rivera,Tiina Korhonen,Anitta Ahonen,Brigitte Cheuvart,Marjan Hezareh,Winnie Janssens,Narcisa Mesaros
Human Vaccines & Immunotherapeutics.2017;13(7)1505
[DOI]
30A randomized, open label trial to evaluate and compare the immunogenicity and safety of a novel liquid hexavalent DTwP-Hib/Hep B-IPV (EasySix™) to licensed combination vaccines in healthy infants
Lalitendu Mohanty,Sunil Sharma,Beauty Behera,Sachin Panwar,Charu Paliwal,Anu Gupta,Deepak Chandra Chilkoti,Anit Singh
Vaccine.2018;36(17)2378
[DOI]
31A randomized, open label trial to evaluate and compare the immunogenicity and safety of a novel liquid hexavalent DTwP-Hib/Hep B-IPV (EasySix™) to licensed combination vaccines in healthy infants
Pragya Misra,Shailza Singh
Vaccine.2020;36(17)1
[DOI]
32DTaP combination vaccine use and adherence: A retrospective cohort study
Matthew M. Loiacono,Vitali Pool,Robertus van Aalst
Vaccine.2021;39(7)1064
[DOI]
33COVID-19 and Seasonal Influenza Vaccination: Cross-Protection, Co-Administration, Combination Vaccines, and Hesitancy
Alexander Domnich,Andrea Orsi,Carlo-Simone Trombetta,Giulia Guarona,Donatella Panatto,Giancarlo Icardi
Pharmaceuticals.2022;15(3)322
[DOI]
34Surveillance on the adverse events following immunization with the pentavalent vaccine in Zhejiang, China
Xuejiao Pan,Huakun Lv,Hui Liang,Ying Wang,Linzhi Shen,Fuxing Chen,Yaping Chen,Yu Hu
Human Vaccines & Immunotherapeutics.2022;18(1)322
[DOI]
35Integration of hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B virus, inactivated poliomyelitis and Haemophilus influenzae type b conjugate vaccine within existing national recommendations following a birth dose of monovalent hepatitis B virus vaccine: results of a systematic review in the Asia Pacific region
Jan Dolhain,Winnie Janssens,Woo-Yun Sohn,Vasundhara Dindore,Piyali Mukherjee
Expert Review of Vaccines.2019;18(9)921
[DOI]
36Hexavalent Vaccines in India: Current Status
Amar Jeet Chitkara,Raunak Parikh,Attila Mihalyi,Shafi Kolhapure
Indian Pediatrics.2019;56(11)939
[DOI]
37Protection against fowl cholera in ducks immunized with a combination vaccine containing live attenuated duck enteritis virus and recombinant outer membrane protein H of Pasteurella multocida
Nisachon Apinda,Boondarika Nambooppha,Amarin Rittipornlertrak,Pallop Tankaew,Veerasak Punyapornwithaya,Venugopal Nair,Takuo Sawada,Nattawooti Sthitmatee
Avian Pathology.2020;49(3)221
[DOI]
38Hexavalent vaccines in infants: a systematic literature review and meta-analysis of the solicited local and systemic adverse reactions of two hexavalent vaccines
Piyali Mukherjee,Essè Ifèbi Hervé Akpo,Anastasia Kuznetsova,Markus Knuf,Sven-Arne Silfverdal,Pope Kosalaraksa,Attila Mihalyi
Expert Review of Vaccines.2021;20(3)319
[DOI]
39Hexavalent vaccines in infants: a systematic literature review and meta-analysis of the solicited local and systemic adverse reactions of two hexavalent vaccines
Federico Martinón-Torres
Expert Review of Vaccines.2017;20(3)183
[DOI]
40New perspectives for hexavalent vaccines
Pablo Obando-Pacheco,Irene Rivero-Calle,José Gómez-Rial,Carmen Rodríguez-Tenreiro Sánchez,Federico Martinón-Torres
Vaccine.2018;36(36)5485
[DOI]
41Combination of three virus-derived nanoparticles as a vaccine against enteric pathogens; enterovirus, norovirus and rotavirus
Suvi Heinimäki,Minna M. Hankaniemi,Amir-Babak Sioofy-Khojine,Olli H. Laitinen,Heikki Hyöty,Vesa P. Hytönen,Timo Vesikari,Vesna Blazevic
Vaccine.2019;37(51)7509
[DOI]
42Vaxelis® (DTaP5-HB-IPV-Hib vaccine) as primary and booster vaccination in infants and toddlers: a profile of its use
Gillian M. Keating,Katherine A. Lyseng-Williamson,Yahiya Y. Syed
Drugs & Therapy Perspectives.2017;33(5)208
[DOI]
43Immunogenicity and safety of a combined DTPa-IPV/Hib vaccine administered as a three-dose primary vaccination course in healthy Korean infants: phase III, randomized study
Ki Hwan Kim,Chun Soo Kim,Hwang Min Kim,Jong-Duck Kim,Sang Hyuk Ma,Dong Ho Kim,Pyoung-Han Hwang,Ji-Whan Han,Taek-Jin Lee,Joon Hyung Kim,Naveen Karkada,Narcisa Mesaros,Woo-Yun Sohn,Jong-Hyun Kim
Human Vaccines & Immunotherapeutics.2019;15(2)317
[DOI]
44Efficacy, safety, and formulation issues of the combined vaccines
Say-yed Hesameddin Tafreshi
Expert Review of Vaccines.2020;19(10)949
[DOI]
45Combination vaccines against diarrheal diseases
Malabi M. Venkatesan,Lillian L. Van de Verg
Human Vaccines & Immunotherapeutics.2015;19(10)00
[DOI]
46Stability of Vaccines
N. Dumpa,K. Goel,Yuhan Guo,H. McFall,Amit Raviraj Pillai,Ashay Shukla,M. A. Repka,S. Narasimha Murthy
AAPS PharmSciTech.2019;20(2)00
[DOI]
47Modern Subunit Vaccines: Development, Components, and Research Opportunities
Peter Michael Moyle,Istvan Toth
ChemMedChem.2013;8(3)360
[DOI]
48Immunogenicity and safety of a combined DTPa-IPV/Hib vaccine administered as a three-dose primary vaccination course and a booster dose in healthy children in Russia: a phase III, non-randomized, open-label study
Victor Romanenko,Irina Osipova,Anna Galustyan,Michael Scherbakov,Nathalie Baudson,Déborah Farhi,Luis Anaya,Sherine O. Kuriyakose,Nadia Meyer,Winnie Janssens
Human Vaccines & Immunotherapeutics.2020;16(9)2265
[DOI]
49Polyvalent vaccines: High-maintenance heroes
Barbara Schlingmann,Katelyn R. Castiglia,Christopher C. Stobart,Martin L. Moore,Katherine R. Spindler
PLOS Pathogens.2018;14(4)e1006904
[DOI]
50A Conjugate Vaccine Using Enantiopure Hapten Imparts Superior Nicotine-Binding Capacity
Jonathan W. Lockner,Jenny M. Lively,Karen C. Collins,Janaína C. M. Vendruscolo,Marc R. Azar,Kim D. Janda
Journal of Medicinal Chemistry.2015;58(2)1005
[DOI]
51Immunogenicity and safety following primary and booster vaccination with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus andHaemophilus influenzaetype b vaccine: a randomized trial in the United States
Nicola P. Klein,Remon Abu-Elyazeed,Brigitte Cheuvart,Winnie Janssens,Narcisa Mesaros
Human Vaccines & Immunotherapeutics.2019;15(4)809
[DOI]
52Immunogenicity and safety following primary and booster vaccination with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus andHaemophilus influenzaetype b vaccine: a randomized trial in the United States
Karen C. Collins,Kim D. Janda
Human Vaccines & Immunotherapeutics.2016;15(4)327
[DOI]
53Immunogenicity and safety following primary and booster vaccination with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus andHaemophilus influenzaetype b vaccine: a randomized trial in the United States
Michael P. Veve,Vasilios Athans
Human Vaccines & Immunotherapeutics.2018;40(4)383
[DOI]
54Hexavalent vaccines: increasing options for policy-makers and providers. A review of the data supporting interchangeability (substitution with vaccines containing fewer antigens) and mixed schedules from the same manufacturer
Jan Dolhain,Winnie Janssens,Narcisa Mesaros,Linda Hanssens,Frederik Fierens
Expert Review of Vaccines.2018;17(6)513
[DOI]
55Immunogenicity and protection efficacy of enhanced fitness recombinant Salmonella Typhi monovalent and bivalent vaccine strains against acute toxoplasmosis
Fei-Kean Loh,Sheila Nathan,Sek-Chuen Chow,Chee-Mun Fang
Pathogens and Global Health.2021;115(6)392
[DOI]
56Nanoparticle Vaccines Against Infectious Diseases
Rashmirekha Pati,Maxim Shevtsov,Avinash Sonawane
Frontiers in Immunology.2018;9(6)392
[DOI]
57The study of the therapeutic effectiveness of the associated inactivated and subunit vaccines based on Candida albicans and Candida tropicalis fungi
Mykola Rybalkin,Natalia Khokhlenkova,Yuliia Azarenko,Olha Kaliuzhnaia,Illya Podolsky
Pharmacia.2021;68(1)89
[DOI]
58The study of the therapeutic effectiveness of the associated inactivated and subunit vaccines based on Candida albicans and Candida tropicalis fungi
Maria Montoya,Elma Z. Tchilian
Pharmacia.2021;68(1)11
[DOI]
59Dual Plug-and-Display Synthetic Assembly Using Orthogonal Reactive Proteins for Twin Antigen Immunization
Karl D. Brune,Can M. Buldun,Yuanyuan Li,Iona J. Taylor,Florian Brod,Sumi Biswas,Mark Howarth
Bioconjugate Chemistry.2017;28(5)1544
[DOI]
60Was Aldo Castellani the inventor of combined and polyvalent vaccines?
Luca Borghi,Elisabetta Riva
Vaccine.2021;39(38)5442
[DOI]
61Safety and long-lasting immunity of the combined administration of a modified-live virus vaccine against porcine reproductive and respiratory syndrome virus 1 and an inactivated vaccine against porcine parvovirus and Erysipelothrix rhusiopathiae in breeding pigs
Almudena Sánchez-Matamoros,Agustí Camprodon,Jaime Maldonado,Rafael Pedrazuela,Joel Miranda
Porcine Health Management.2019;5(1)5442
[DOI]
62Life-Course Approach to Vaccination in Bangladesh for Meeting the Health and Health-Related Sustainable Development Goals: A Commentary
Taufiqur Rahman Bhuiyan,Taufiqul Islam,Firdausi Qadri
The Journal of Infectious Diseases.2021;224(Supplement_7)S749
[DOI]
63Peculiarities of Zika Immunity and Vaccine Development: Lessons from Dengue and the Contribution from Controlled Human Infection Model
Helton C. Santiago,Tertuliano A. Pereira-Neto,Marcela H. Gonçalves-Pereira,Ana C. B. Terzian,Anna P. Durbin
Pathogens.2022;11(3)294
[DOI]
64Impact of combination MMRV vaccine on first-dose coverage for measles and varicella: a population-based study
Shannon E. MacDonald,Suzanne Tough,Xiaoyan Guo,James D. Kellner
Journal of Public Health.2022;30(5)1063
[DOI]
  Addresses 
  My Preferences 


JGID
What's new
Forthcoming Symposia
Submit articles
Email alerts
Join us
Most popular articles
Recommend this journal
Sitemap | What's New | Feedback | Copyright and Disclaimer | Privacy Notice | Contact Us
© 2008 Journal of Global Infectious Diseases | Published by Wolters Kluwer - Medknow
Online since 10th December, 2008